COPD is one of the nation’s most serious health problems, affecting over 24 million Americans. The condition created direct and indirect costs of nearly $50 billion in 2010, according to the American ...

Nucala's growth is driven by a strong commercial base, expansion into COPD treatment after U.S. and European approvals, and a diversified multi-indication use including asthma and nasal polyps. This ...